The Institute for Clinical and Economic Review (ICER) confirmed in a recent report that evidence is lacking for outcomes comparisons of ploy-ADP ribose polymerase (PARP) inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.
A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer, published in the Journal of Clinical Oncology (October 2017;35:3347-3353).
Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in progression-free survival (PFS) with a specific maintenance therapy, regardless of their disease characterization.
A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers, according to research published in Precision Oncology (published online May 2017; doi:10.1038/s41698-017-0008-z).
Common comorbidities such as hypertension, heart disease, and diabetes may contribute to a woman’s prognosis after being diagnosed with ovarian cancer, according to a study published in Cancer Causes Control (2017;28:469-486).
Women with stage II-IV low-grade serous carcinoma of the ovary or peritoneum who received hormonal maintenance therapy after primary treatment had longer progression-free survival (PFS) compared with women who underwent routine observation after primary treatment.
Primary cytoreductive surgery (PCS) is better than neoadjuvant chemotherapy (NACT) for overall survival in women aged 70 years or younger with advanced-stage epithelial ovarian cancer (EOC), according to a recent study published in JAMA Oncology.